Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

Fig. 2

Mean change in (A) monthly migraine days/monthly headache days (MMDs/MHDs), B Numerical Rating Scale (NRS) score, C monthly analgesic medications, D Headache Impact Test-6 (HIT-6) score and (E) Migraine Disability Assessment Scale (MIDAS) score from baseline to week 24 in patients from headache centers providing efficacy data at week 12 and 24 (n = 148). HFEM, high-frequency episodic migraine; CM, chronic migraine

Back to article page